Why the study?
Does bezafibrate reduce cardiovascular outcomes and arterial disease progression in type 2 diabetic subjects without a history of clinical cardiovascular disease?
Population
164 type 2 diabetic subjects (117 men, 47 women) without a history of clinical cardiovascular disease
Comparison
Bezafibrate daily in addition to routine… vs Placebo daily in addition to routine diabetes…
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
minimum of 3 years
Authors
Loading...
Bezafibrate reduces combined ischemic events and MI in T2DM without prior CVD; extends fibrate outcome data independent of arterial progression.
Does bezafibrate reduce cardiovascular outcomes and arterial disease progression in type 2 diabetic subjects without a history of clinical cardiovascular disease?
In type 2 diabetic patients without prior cardiovascular disease, bezafibrate improved lipid profiles and reduced definite CHD events, although it did not alter the progression of ultrasonically measured arterial disease.
Elkeles et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: